Ledger.Open graph →

SEC Form D · Amendment · filed September 18, 2023

Renibus Therapeutics, Inc

Offering

$103.4M

Sold

$95.9M

Exemption

Rule 506(b)

Industry

Pharmaceuticals

Location

SOUTHLAKE, TX

Type

—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (18)

Frank J. Stonebanks · Southlake, TXExec · Director Jamie J. Donadio · Southlake, TXExec Henrik J. Rasmussen · Southlake, TXDirector Bhupinder J. Singh · Southlake, TXExec · Director D. J. Keyser · Southlake, TXExec · Director Carlos Guillem · Southlake, TXDirector Brice Penaud · Austin, TXExec · Director Kevin Thueson · Cheyenne, WYDirector Theodore J. Moskovitz · Austin, TXExec George Quinoy · Woburn, MAExec · Director Brian J. Palmer · Fort Worth, TXDirector D'Ambrosio Trent · Murray, UTExec · Director Lara A. Cumberland · Cincinnati, OHExec · Director Vincent Gubitosi · Newton, MADirector Selim Dogguy · Chicago, ILDirector Pavel Mucha · Chicago, ILExec · Director Christopher N. Richardson · Minneapolis, MNExec Paul B. Allen · Jameson, MOExec · Director

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗